Factor XIs: Are They the Knockout Round in Next Phase Antithrombotic Therapies?
Saturday, March 29 ● 5:30 – 7 p.m. (Doors open at 5 p.m.)
Town Hall, S100A

Join Geoffrey D. Barnes, MD, MSc, FACC, and a team of expert faculty for an engaging, interactive session that explores the benefits and risks of key anticoagulation therapies — vitamin K antagonists (VKAs), direct oral anticoagulants (DOACs), and factor XI inhibitors. This session will provide a comprehensive comparison of these therapies, highlighting their unique benefits, limitations, and clinical applications in managing patients with atrial fibrillation (AFib), acute coronary syndromes (ACS), and comorbid conditions such as end-stage renal disease (ESRD) and cancer. Gain a deeper understanding of the role factor XI plays in both hemostasis and thrombosis, and how these insights impact clinical decision-making. Additionally, our faculty will discuss the importance of employing multidisciplinary approaches to develop effective, patient-centered care pathways, ensuring optimal outcomes in these complex clinical scenarios.

Supported by an educational grant from the Bristol Myers Squibb and Janssen Pharmaceuticals, Inc. Alliance.

In the Hot Seat: Experts Weigh In on Weight Management
Saturday, March 29 ● 5:30 – 7 p.m. (Doors open at 5 p.m.)
Room S100B

Join session chair Leslie Cho, MD, FACC, and our expert faculty for an insightful discussion on the challenges of managing cardiovascular and cardiometabolic care in patients with comorbidities such as obesity, diabetes, and heart failure. This session will delve into the complexities of providing comprehensive cardiology care in the presence of these comorbidities, as well as other patient considerations. Explore current and emerging anti-obesity medications (AOMs) and their role in improving cardiovascular health, while learning to develop effective weight-management care plans that integrate both lifestyle interventions and pharmacologic strategies to optimize patient outcomes.

Supported by an educational grant from Novo Nordisk.

Mastering AFib Monitoring and Ablation: Advanced Cases and Practical Insights
Sunday, March 30 ● 7 – 8:30 p.m. (Doors open at 6:30 p.m.)
Town Hall, S100A

Join Stavros Mountantonakis, MD, MBA, FACC, as he guides you through the integration of updated ablation techniques and guideline-based practices into personalized treatment plans for atrial fibrillation (AFib). This session will explore the latest advancements in AFib management, emphasizing how to incorporate state-of-the-art ablation techniques to improve patient outcomes. Learn to evaluate the role of emerging technologies in AF monitoring, assessing how these tools contribute to the effective management of disease progression and help in tailoring more precise treatment strategies. In addition, Dr. Mountantonakis will highlight the existing disparities in AF care and provide actionable strategies to ensure timely and equitable access to advanced interventions, particularly for underserved populations, ensuring that all patients receive the best possible care.

Supported by educational grants from Biosense Webster, Inc., Boston Scientific Corporation and Medtronic.

The Amyloid Files: Cracking the Case – Evolving Strategies in Cardiac Amyloidosis
Sunday, March 30 ● 7 – 8:30 p.m. (Doors open at 6:30 p.m.)
Room S100B

Join Ronald Witteles, MD, FACC, for an in-depth session focused on recognizing the diverse and often subtle clinical presentations of cardiac amyloidosis, emphasizing the critical need for early detection and differentiation from other common cardiac conditions. This session will provide you with a comprehensive understanding of how to identify cardiac amyloidosis, particularly transthyretin amyloid cardiomyopathy (ATTR-CM), through advanced diagnostic techniques and clinical performance measures. Dr. Witteles will discuss the latest diagnostic tools and treatment protocols, enabling clinicians to refine their diagnostic approach and enhance care for these patients. Additionally, the session will explore how a multidisciplinary approach is crucial in developing effective care pathways, ensuring comprehensive management that addresses the complexities of this often underdiagnosed condition, and ultimately improving patient outcomes through collaborative, patient-centered care.

Supported by educational grants from Alnylam, AstraZeneca, and BridgeBio Pharma, Inc.